NGS Acquires World’s First Approved Plant-Based Infant Formula in $8M Deal
NGS acquires the world’s first FSANZ-approved plant-based infant formula in transformational deal
Nutritional Growth Solutions Limited (ASX: NGS) has entered a binding Share Sale Agreement to acquire 100% of Sprout Organic Pty Ltd, combining Sprout’s 0–3 years infant and toddler range with NGS’s Healthy Heights 3–10+ years products to create a complete 0-to-teen nutritional pathway. The acquisition consideration is approximately A$8.0 million, satisfied by the issue of 401,228,887 NGS shares at a deemed issue price of A$0.02 per share. Separately, the company has received firm commitments to raise A$2.5 million via a placement of 125,000,000 shares at A$0.02 per share, alongside approximately A$870,000 in identified annualised cost savings. Both the Transaction and the placement remain subject to shareholder approval at the AGM, expected in approximately July 2026.
Transaction at a glance
| Detail | Acquisition | Placement | Combined | Notes |
|---|---|---|---|---|
| Consideration / Raise Amount | ~A$8.0M | A$2.5M | ~A$10.5M | Placement is before costs |
| Shares Issued | 401,228,887 NGS shares | 125,000,000 NGS shares | 526,228,887 NGS shares | Both are fully paid ordinary NGS shares |
| Price Per Share | A$0.02 (deemed issue price) | A$0.02 | — | A$0.02 refers to NGS shares only; no Sprout-level share price is disclosed |
| Escrow Condition | ~90% of major Sprout shareholders’ consideration shares subject to 12 months’ voluntary escrow from date of issue | Not applicable | — | Voluntary escrow applies to acquisition consideration shares only |
| AGM / Approval Timeline | Subject to shareholder approval | Subject to shareholder approval | ~6 weeks from announcement | Expected ~July 2026 |
When big ASX news breaks, our subscribers know first
Why Sprout fills a gap no other product has closed
Australia has one of the highest rates of childhood food allergy in the world on a per-capita basis, frequently described as the “allergy capital of the world.” Up to 10% of Australian infants are affected by an allergy, and more than 2% have cow’s milk protein allergy, according to ASCIA and the Murdoch Children’s Research Institute.
For families managing allergen-sensitive infants, conventional dairy- and soy-based formulas are simply not viable options. This creates what the announcement describes as a structural, “forced” demand driver: parents do not choose a plant-based formula as a lifestyle preference but because no safe alternative exists. The demand is non-discretionary, making it more resilient than typical consumer preferences.
Consumer sentiment is also shifting independently of allergy prevalence. Approximately 72% of Millennials with children express a strong interest in plant-based foods, according to GlobeScan and EAT’s “Grains of Truth” 2024 report. Combined with the allergy-driven necessity segment, this creates a broad and growing addressable market.
Sprout developed the world’s first FSANZ-approved 100% organic, plant-based infant formula in direct response to this unmet need. FSANZ (Food Standards Australia New Zealand) is the joint Australian-New Zealand regulatory authority governing food standards, and its approval process represents a material barrier to entry that existing competitors have not cleared for a fully plant-based infant formula.
The reasons no direct global equivalent exists are multi-layered:
- FSANZ approval is a significant regulatory barrier that limits competitive entry
- The formula is free from dairy, soy and common allergens
- Backed by proprietary formulation IP and provisional patents
- No direct global equivalent product has been approved under a comparable regulatory framework
This regulatory moat, combined with the structural demand drivers, positions Sprout in a category where competitive displacement is constrained by both science and regulation.
A single brand relationship from birth to adolescence
Closing the “brand switch” problem
Parents currently face a recurring challenge: trusted nutrition brands typically serve a narrow age window, forcing families to switch products every 2–3 years as a child’s needs evolve. Each transition introduces renewed uncertainty around allergens, formulation safety and taste acceptance. No single player has historically owned the full “infant-to-teen” relationship, and this white space is precisely what the combined NGS and Sprout platform is built to address.
The combined product lifecycle spans the full period of childhood development:
- Sprout Infant Formula (0–1 yr)
- Sprout Follow-on & Toddler Drink (1–3 yrs)
- Healthy Heights Grow Daily 3+ (3–9 yrs)
- Healthy Heights Grow Daily 10+ (10+ yrs)
For investors, the significance is structural: a customer acquired at birth through Sprout’s infant formula can remain within the combined brand ecosystem through adolescence. The lifetime value of each customer relationship extends materially beyond what either business could capture independently.
Cross-selling and cost savings — no capex required
The two businesses share an asset-light operating model, meaning integration synergies are available almost immediately on completion without capital expenditure.
Revenue cross-sell opportunities:
- Sprout’s plant-based range to be launched into NGS’s U.S. Amazon and iHerb channels
- Healthy Heights to enter Sprout’s national pharmacy network and China distribution footprint
- Shared Shopify and Amazon storefronts reduce customer acquisition cost across both brands
Cost savings (attributable to the acquisition and integration):
- Approximately A$870,000 in annualised savings identified
- Approximately US$600,000 activated immediately on completion
- Savings sourced from shared corporate functions, reduced listing and director fees, back-office consolidation, and a unified 3PL model (Better Brands AU and AMZ Prep US)
The asset-light model is central to the investment thesis. With 100% outsourced GMP/HACCP manufacturing across both businesses, integration carries zero capex requirement and the combined entity can scale distribution without needing to build or acquire physical infrastructure.
Manik Pujara, Executive Director & Interim CEO
“This is a genuinely transformational acquisition for NGS. Sprout has built something rare — the world’s first FSANZ-approved 100% organic, plant-based infant formula — alongside strong retail and export distribution and attractive gross margins.”
Selasi Berdie, Incoming CEO & Sprout Founder
“Sprout and NGS are a natural fit — premium, clean-label and clinically supported products, and a shared focus on children’s nutrition.”
The next major ASX story will hit our subscribers first
Leadership, capital structure and next steps
A refreshed leadership team
The following appointments are subject to shareholder approval and completion of the Transaction:
- Selasi Berdie (Sprout Founder & CEO) appointed NGS CEO & Executive Director
- Ben Chester (Sprout COO) appointed Group COO
- Manik Pujara (current Executive Director & Interim CEO) transitions to Non-Executive Director
Indicative combined financials and timetable
The table below presents CY2025 indicative financials (1 January 2025 – 31 December 2025). NGS figures are audited; Sprout figures are unaudited; combined group figures are therefore unaudited. These figures do not include the identified annualised cost savings.
| Metric | NGS (audited) | Sprout (unaudited) | Combined Group (unaudited) |
|---|---|---|---|
| Annual Revenue (USD) | $1,627,301 | $3,704,757 | $5,332,058 |
| Annual Profit/(Loss) before tax (USD) | ($1,591,414) | ($23,113) | ($1,806,403) |
| Consolidated EBITDA (USD) | ($1,369,024) | ($99,464) | ($1,468,488) |
The indicative timetable for the Transaction is as follows:
- Trading resumption: Immediately following this announcement
- AGM to approve Transaction and Placement: Approximately 6 weeks from announcement (expected ~July 2026)
- Settlement of Placement shares: Shortly after AGM approval
As a proof-of-traction signal, Sprout’s products are already sold through more than 1,000 retail outlets nationally, including Chemist Warehouse, Woolworths Online, Coles Online and leading pharmacy networks. The business also maintains an active export presence across China, New Zealand, Malaysia and the UAE, providing the combined group with established international distribution channels from day one.
Don’t Miss the Next Consumer Healthcare Breakout
Big News Blast delivers FREE breaking ASX news from the Consumer and Healthcare sectors directly to your inbox within minutes of release, complete with in-depth analysis already done. Join 20,000+ subscribers staying ahead of the market the moment announcements drop. Click the “Free Alerts” button at Big News Blast to start receiving alerts today.